medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Title: Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness

Authors: Korryn Bodner[1], Jesse Knight[1,2], Mackenzie A. Hamilton[1], and Sharmistha Mishra[1,2,3,4]

[1] MAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada

[2] Institute of Medical Science, University of Toronto, Toronto, Canada

[3] Division of Epidemiology and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

[4] Department of Medicine, University of Toronto, Canada

Keywords: vaccine effectiveness; vaccine efficacy; SARS-CoV-2; transmission model; bias

Running Title: Contact influences vaccine effectiveness

Corresponding Author:

Korryn Bodner

Rm 326.1, 3rd Floor, St. Michael's Hospital, Unity Health Toronto

209 Victoria Street, 3rd Floor

Toronto, Ontario, Canada, M5B 1T8

Phone: +1-416-864-5746

Fax: +1-416-864-5310

Email: k.bodner@mail.utoronto.ca

Alternate Corresponding Author:

Sharmistha Mishra

Rm 315, 3rd Floor, St. Michael's Hospital, Unity Health Toronto

209 Victoria Street, 3rd Floor

Toronto, Ontario, Canada, M5B 1T8

Phone: +1-416-864-5746

Fax: +1-416-864-5310

Email: sharmistha.mishra@utoronto.ca

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

This work was supported by the Canada COVID-19 Immunity Task Force grant (to SM)

All authors declare that they have no conflicts of interest.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Contact influences vaccine effectiveness

Abstract: Evidence from early observational studies suggested negative vaccine effectiveness for the SARS-CoV-2 Omicron variant. Using transmission modeling, we illustrated how increased contact between vaccinated individuals, vaccinated contact heterogeneity, paired with lower vaccine efficacies could produce negative measurements and how we can identify this mechanism via a key temporal signature.

Introduction:

Within 4 weeks of the emergence and in the context of rising cases of Omicron, population-based studies in Canada [1], Denmark [2], and the United Kingdom [3] had reported "negative vaccine effectiveness" against SARS-CoV-2. Vaccine effectiveness (V_{Eff}) is calculated by comparing the rates of infection between vaccinated and unvaccinated individuals. Thus, a negative V_{Eff} measurement suggests that vaccinated individuals were acquiring infections at higher rates than unvaccinated individuals. One potential explanation for the increased infection was that the vaccine increased biological susceptibility, for example, if the virus had evolved to spread faster in vaccinated individuals [4]. However, V_{Eff} measurements are calculated using observational data and thus subject to various biases, including but not limited to differences in testing/detection and exposures among vaccinated and unvaccinated populations [5]. Differential exposures by vaccination status could stem from contact heterogeneity.

Contact heterogeneity refers to different levels of contact among and between population subgroups. Increased contact between vaccinated persons, potentially arising due to policies that restrict certain spaces to vaccinated individuals (e.g. vaccine mandates), is one type of contact heterogeneity (hereafter, vaccinated contact heterogeneity). In this study, we test (1) whether vaccinated contact heterogeneity could lead to negative V_{Eff} measurements; (2) how this relationship is affected by two components of vaccine efficacy related to transmissibility: vaccine efficacy against susceptibility (VE_S) and vaccine efficacy against infectiousness (VE_I) [6]; and if negative measurements

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

can be produced, (3) how this mechanism can be identified. $\mathrm{VE_S}$ and $\mathrm{VE_I}$ reflect the true total vaccine benefit against infection, with $\mathrm{VE_S}$ reflecting the reduced probability of vaccinated recipients acquiring infection and $\mathrm{VE_I}$ reflecting the reduced infectiousness of vaccinated individuals if a breakthrough infection occurs. We hypothesize that both vaccinated contact heterogeneity and the levels of $\mathrm{VE_S}$ and $\mathrm{VE_I}$ contribute to producing negative V_{Eff}.

Methods:

Following Shim and Galvani [7], we adapted a simple compartmental SIR (susceptible, infectious, recovered) transmission dynamics model for vaccinated and unvaccinated individuals that assumed an all-or-nothing vaccine type (supplementary Figure 1, [8]). To explicitly account for potential contact differences, the SIR model contained both within-group contact rates for unvaccinated, c_{uu}, and vaccinated individuals, c_{vv}, as well as between-group contact rates for unvaccinated with vaccinated, c_{uv}, and vaccinated with unvaccinated, c_{vu}.

In all simulations, we assumed 75% vaccination coverage. We explored two different contact scenarios: *homogeneous contact*, where vaccinated and unvaccinated individuals have equal contacts with random ("proportionate") mixing; and *vaccinated heterogeneous contact* where vaccinated individuals have increased within-group contact. In the *homogenous contact* scenario, we assumed 6 daily contacts per-person, reflecting approximate contact rates from U.S. and U.K. during the pandemic [9], and thus defined c_{vv}= c_{uv} = 4.5 and c_{uu}= c_{vu}=1.5. In the *vaccinated heterogenous contact* scenario, contacts between vaccinated were increased by 50% compared to the *homogeneous contact* scenario (c_{vv} = 6.75), with all other parameter values unchanged. We set the recovery rate to be 1/10 [8] and the probability of transmission to be 0.01 such that R_0 = 6 in a fully unvaccinated population with random mixing. Given the uncertainty surrounding vaccine efficacies, two different baseline values of $\mathrm{VE_I}$ and $\mathrm{VE_S}$ were adopted (0.1, 0.5). We also conducted sensitivity analyses, varying $\mathrm{VE_I}$ and $\mathrm{VE_S}$ from 0.1 to 1

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

and increasing c_{vv} by 0%- 100% from the *homogenous contact scenario* rates (c_{vv} = 4.5 - 9). To start our simulations, we introduced one infected vaccinated and unvaccinated individual into our population.

Following Haber [9], we measured $V_{Eff}(t)$ as 1 – relative risk (t) (RR[t]), defined as:

$$RR(t) = \frac{\frac{CI_v(t)}{N_v}}{\frac{CI_u(t)}{N_u}} \quad (1)$$

where $CI_v(t)$ and $CI_u(t)$ are the cumulative incidences for vaccinated and unvaccinated groups at time t and N_v and N_u are the total numbers of vaccinated and unvaccinated individuals, respectively. We also tracked how differences in the depletion of the proportion of susceptible vaccinated, $\frac{S_v(t)}{N_v}$, and unvaccinated, $\frac{S_u(t)}{N_u}$, interacted explicitly with $\mathrm{VE_S}$ to influence measurements of $V_{Eff}(t)$ (supplementary Material 1). R-code to recreate all analyses is available on GitHub (https://github.com/kbbodner/contact_and_NegVE)

Results:

First, scenarios of homogeneous contact by vaccination status never led to an observed negative V_{Eff}. Second, scenarios of heterogeneous contact by vaccination status produced negative V_{Eff}, but only in the context of lower vaccine efficacies ($\mathrm{VE_S}$ =0.1, $\mathrm{VE_I}$=0.1, and $\mathrm{VE_S}$=0.1, $\mathrm{VE_I}$=0.5; Figure 1a). Third, negative V_{Eff} only occurred during epidemic growth (Figure 1a and b) with $V_{Eff}(t)$ becoming positive only when the proportion of susceptible unvaccinated was lower than the combined proportion of susceptible vaccinated with the proportion immune due to vaccination (i.e. the level of $\mathrm{VE_S}$; supplementary Figure 2).

The minimum V_{Eff} was moderately influenced by $\mathrm{VE_I}$, and strongly influenced by the levels of $\mathrm{VE_S}$ and the contact between vaccinated individuals (Figure 1c-d). For example, when VE_S was less than

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

0.2 and c_{vv} was a 100% higher than the *homogeneous contact* scenario, $V_{Eff}(t)$ was strongly negative (< -0.5). $\mathrm{VE_I}$ was less influential on negative V_{Eff} but high levels of $\mathrm{VE_I}$, (>0.92) could still prevent negative V_{Eff} even at very low $\mathrm{VE_S}$ (<0.1) (Figure 1c).

Discussion:

Our results demonstrated how vaccinated contact heterogeneity, defined as higher contact levels between vaccinated individuals, could lead to observed measurements of negative V_{Eff}. Thus, we illustrate a plausible scenario where vaccines can be perceived to be non-beneficial - or even harmful – despite providing a benefit to a population (vaccine efficacies > 0).

Vaccinated contact heterogeneity can negatively bias measurements of V_{Eff}, but observing negative measurements required the underlying vaccine efficacies to be lower– in particular, lower $\mathrm{VE_S}$. That is, we found that vaccine efficacies can mediate the effect of the contact heterogeneity bias. Given the consistent reports of higher V_{Eff} against other variants compared to Omicron [e.g. 10], this mediation effect can explain how this bias could be present before Omicron despite the absence of negative measurements.

Beyond testing vaccinated contact heterogeneity feasibility as a mechanism of bias, we also identified a temporal signature in V_{Eff} measurements that indicates when this mechanism could be the cause of negative V_{Eff}. In the context of vaccinated contact heterogeneity, negative measurements only occurred during epidemic growth when the proportion of susceptible unvaccinated was higher than the proportion of susceptible vaccinated (mediated by $\mathrm{VE_S}$; supplementary Figure 2). In each of the empirical studies, the negative V_{Eff} measurements coincided with Omicron's epidemic growth stage [1–3]. If measurements of V_{Eff} are consistently updated and found to change direction later in an epidemic, this would suggest the negative measurement may have been the result of vaccinated contact heterogeneity.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Vaccinated contact heterogeneity is one possible cause of negative V_{Eff}, but other biases such as selection bias via testing access or health-seeking behaviour [5], as well as higher immunity among unvaccinated from prior infection could also potentially cause negative measurements. Moreover, our analysis focused on an all-or-nothing vaccine type for simplicity, but leaky vaccine type [11] could impart a different temporal pattern for the vaccinated contact heterogeneity bias. Important next steps include exploring other potential biases that may lead to negative V_{Eff} and including how assumptions surrounding leaky versus all-or-nothing vaccine type may influence V_{Eff} measures over time.

Although our study was designed to explain potential mechanisms, and not to specify which values of $\mathrm{VE_S}$, VE_I and contact differences most likely cause observed negative measures, the findings have important implications for the conduct and interpretation of observational studies measuring V_{Eff}. If possible, observational studies must try to address confounding due to vaccinated contact heterogeneity when measuring V_{Eff} during epidemic growth as this bias could affect measurements for future variants of SARS-CoV-2 and other emerging pathogens. If it is not possible to address confounding, then reports and public communication must ensure that interpretation of V_{Eff} includes the possibility of this bias to avoid misinterpretation that can amplify vaccine mistrust [12], or wait until the epidemic peak has occurred to update and report measurements of V_{Eff}.

In this brief report, we highlight one possible pathway for V_{Eff} to appear negative even when vaccines are beneficial and how this bias could be identified. Our findings not only illustrate a potential mechanism for the negative V_{Eff} studies of the Omicron variant [1,3], but also provide a potential explanation for observed negative V_{Eff} in future studies.

Funding: This work was supported by the Canada COVID-19 Immunity Task force grant (to SM).

Acknowledgements: We would like to thank Dr. Jeffrey C. Kwong and Sarah A. Buchan for their insight into measuring vaccine effectiveness and KB would like to additionally thank Cedric B. Hunter for their

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ongoing support. JK is supported by the Natural Sciences and Engineering Research Council of Canada (NSERC CGS-D) and SM is supported by a Tier 2 Canada Research Chair in Mathematical Modeling and Program Science.

References

1. Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv **2022**; :2021.12.30.21268565. Available at: https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v2%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.30.21268565v2.abstract.

2. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv **2021**; :iii–iv.

3. UK Health Security Agency. COVID-19 Vaccine Surveillance report: 23 December 2021 (week 51). 2021. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports. Accessed 4 April 2022.

4. Day T, Kennedy DA, Read AF, Gandon S. The evolutionary epidemiology of pathogens during vaccination campaigns. **2021**; :1–32.

5. Weinberg GA, Szilagyi PG. Vaccine epidemiology: Efficacy, effectiveness, and the translational research roadmap. J Infect Dis **2010**; 201:1607–1610.

6. Halloran ME, Longini IM, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev **1999**; 21:73–88.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

7. Shim E, Galvani AP. Distinguishing vaccine efficacy and effectiveness. Vaccine **2012**; 30:6700–6705.

8. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol **1984**; 13:87–93.

9. Haber, M. Estimation of the direct and indirect effects of vaccination. Stat Med **1999**; 18:2101–2109.

10. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med **2022**; 19.

11. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of vaccine direct effects under the test-negative design. Am J Epidemiol **2018**; 187:2686–2697.

12. Miller A. Canadian COVID-19 vaccine study seized on by anti-vaxxers — highlighting dangers of early research in pandemic. CBC. 2022; Available at: https://www.cbc.ca/news/health/covid-19-vaccine-study-omicron-anti-vaxxers-1.6315890.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.25.22274266; this version posted May 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Vaccine effectiveness and infection dynamics are influenced by contact heterogeneity and vaccine efficacies. Homogeneous contact rates (equal contacts among vaccinated and unvaccinated individuals) and heterogenous contact rates (vaccinated have more contacts with vaccinated individuals) interact with vaccine efficacy against susceptibility ($\mathrm{VE_S}$) and vaccine efficacy against infectiousness ($\mathrm{VE_I}$) to influence measurements of vaccine effectiveness over time (a) and the proportion of infected individuals over time (b). Negative vaccine effectiveness becomes positive once the proportion of susceptible unvaccinated individuals became lower than the proportion of susceptible vaccinated individuals combined with the level of $\mathrm{VE_S}$ (grey vertical lines; supplementary Material 1). The minimum vaccine effectiveness was sensitive to $\mathrm{VE_I}$ (c), the % increase in contact between vaccinated individuals (d), and $\mathrm{VE_S}$ (c and d). Note that colours in (c) and (d) indicate the minimum negative vaccine effectiveness observed for a given simulation with >0 indicating a non-negative measurement.